These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17328231)

  • 1. Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.
    Toniutto P; Fabris C; Bitetto D; Fornasiere E; Rapetti R; Pirisi M
    Curr Opin Investig Drugs; 2007 Feb; 8(2):150-8. PubMed ID: 17328231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of 1'-C-cyano pyrimidine nucleosides and characterization as HCV polymerase inhibitors.
    Kirschberg TA; Mish M; Squires NH; Zonte S; Aktoudianakis E; Metobo S; Butler T; Ju X; Cho A; Ray AS; Kim CU
    Nucleosides Nucleotides Nucleic Acids; 2015; 34(11):763-85. PubMed ID: 26398773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
    Mederacke I; Wedemeyer H; Manns MP
    Curr Opin Investig Drugs; 2009 Feb; 10(2):181-9. PubMed ID: 19197796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoramidate prodrugs deliver with potency against hepatitis C virus.
    Mehellou Y
    ChemMedChem; 2010 Nov; 5(11):1841-2. PubMed ID: 20865770
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon-based therapy of hepatitis C.
    Chevaliez S; Pawlotsky JM
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1222-41. PubMed ID: 17869375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein.
    Chemmanur AT; Wu GY
    Curr Opin Investig Drugs; 2006 Aug; 7(8):750-8. PubMed ID: 16955687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-nucleoside analogue polymerase inhibitors in development.
    Pockros PJ
    Clin Liver Dis; 2013 Feb; 17(1):123-8. PubMed ID: 23177288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
    Wagner R; Larson DP; Beno DW; Bosse TD; Darbyshire JF; Gao Y; Gates BD; He W; Henry RF; Hernandez LE; Hutchinson DK; Jiang WW; Kati WM; Klein LL; Koev G; Kohlbrenner W; Krueger AC; Liu J; Liu Y; Long MA; Maring CJ; Masse SV; Middleton T; Montgomery DA; Pratt JK; Stuart P; Molla A; Kempf DJ
    J Med Chem; 2009 Mar; 52(6):1659-69. PubMed ID: 19226162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.
    Bosse TD; Larson DP; Wagner R; Hutchinson DK; Rockway TW; Kati WM; Liu Y; Masse S; Middleton T; Mo H; Montgomery D; Jiang W; Koev G; Kempf DJ; Molla A
    Bioorg Med Chem Lett; 2008 Jan; 18(2):568-70. PubMed ID: 18068361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
    Gatti F; Nasta P; Matti A; Manno D; Mendeni M; Puoti M; Carosi G
    AIDS Rev; 2007; 9(1):16-24. PubMed ID: 17474310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of ATP-binding site directed potential inhibitors of nucleoside triphosphatases/helicases and polymerases of hepatitis C and other selected Flaviviridae viruses.
    Bretner M; Schalinski S; Haag A; Lang M; Schmitz H; Baier A; Behrens SE; Kulikowski T; Borowski P
    Antivir Chem Chemother; 2004 Jan; 15(1):35-42. PubMed ID: 15074713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.